Comparison of inravitreal ranibizumab therapy with and without laser photocoagulation for diabetic macular edema.

Comparison of inravitreal ranibizumab therapy with and without laser photocoagulation for diabetic macular edema. - Comparison of inravitreal ranibizumab therapy with and without laser photocoagulation for diabetic macular edema.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024697

Enrollment

100

Registered

2016-11-07

Start date

2015-08-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic macular edema

Interventions

Ranibizumab monotherapy Ranibizumab/Laser photocoagulation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Over 20 years old. HbA1c under 10%. Diabetic macular edema with central subfield thickness over 250um. Best-correctd visual acuity over 20/200.

Exclusion criteria

Exclusion criteria: Other ocular disease. Laser photocoagulation within 3 months. Anti-VEGF therapy within 3 months. Focal steroid injection within 3 months. Diabetic retinopthy over 85 ETDRS grades. After any vitrectomy. After cataract surgery. Focal diabetic macular edema.

Design outcomes

Primary

Measure	Time frame
The change from baseline in best-crrected visual acuity at 18 months.	—

Countries

Japan

Contacts

Public ContactShigehiko Kitano

Tokyou Women's Medicai University Department of Ophthalomology, Diabetes Center

ge2s-ktn@asahi-net.or.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026